Monday, December 17, 2012

Perrigo's FY 2013 guidance as a proxy to TARO

Read, understand and consent to the blog's DISCLAIMER here before proceeding to read the article

Perrigo's guidance for it's RX Topical business bodes well for its competitor TARO. Perrigo is guiding for 15-19% Growth year on year. This is after registering >30% Year-on-Year growth in the last 4 years. Hopefully, TARO's management will update it's guidance and trash the highly inaccurate June 14th estimates.

No comments:

Post a Comment